Braftovi/Mektovi (encorfenib/binimetinib)
pCPA File Number:
21544
Negotiation Status:
Concluded with an LOI
Indication(s):
Unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test, (encorafenib and binimetinib in combination)
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
PC0232-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: